Advancing precision medicine with personalized drug screening

Area of Science:

• Biomedical Science
• Pharmacology
• Genomics

Background:

• Personalized drug screening (PDS) utilizes approved drug libraries for rapid development of patient-specific small-molecule therapies.
• A multidisciplinary approach involving clinicians, researchers, ethicists, informaticians, and regulatory professionals is crucial for optimizing PDS.
• PDS offers a pathway to identify effective treatments for diseases with no current therapeutic options.

Purpose of the Study:

• To review the application of PDS in addressing various diseases, including cancer and bacterial infections.
• To highlight the potential of PDS in optimizing patient treatment efficacy and minimizing adverse effects.
• To explore the synergistic role of PDS and personal genomic analyses in advancing precision medicine.

Main Methods:

• Review of existing PDS campaigns and their outcomes across different medical conditions.
• Analysis of the multidisciplinary team's role in successful PDS implementation.
• Integration of personal genomic data with PDS strategies.

Main Results:

• PDS has demonstrated success in developing targeted therapies for specific patient needs.
• Optimized treatment strategies through PDS lead to improved efficacy and reduced adverse events.
• PDS has identified potential therapeutics for diseases previously lacking treatment options.

Conclusions:

• Personalized drug screening is a viable strategy for developing tailored therapies.
• The integration of PDS with genomic analysis is a key component of future precision medicine.
• PDS holds significant promise for treating a wide range of diseases, including rare and complex conditions.